


Metoprolol tartrate

Chemical Properties

CAS No. : 56392-17-7
 Formula: C₁₅H₂₅NO₃.2:1C₄H₆O₆
 Molecular Weight: 684.81
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	Metoprolol Tartrate is a blocker of the cardioselective β -adrenergic receptor.
Targets(IC50)	Apoptosis, Adrenergic Receptor
In vitro	Metoprolol, attenuates cardiomyocyte apoptosis in left ventricular (LV) myocardium of dogs with heart failure (HF). Metoprolol induces the expression of Bcl-2 independent of heart failure (HF) and that this independently confers protection. [1]
In vivo	Metoprolol partly reverses the depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks myocardial infarction (MI) rats. Metoprolol partially reverses the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine. [2] Metoprolol treatment attenuates the development of cardiac dysfunction in streptozotocin (STZ)-diabetic rats. Metoprolol leads to reduced rates of palmitate oxidation, stimulation of glucose oxidation, and increases tissue ATP levels. Metoprolol leads to decreased maximum activity and decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA. Metoprolol also increases sarco(endo) plasmic reticulum Ca(2+)-ATPase expression and prevents the reexpression of atrial natriuretic peptide in diabetic hearts of in streptozotocin (STZ)-diabetic rats. [3] Metoprolol, attenuates the increase in collagen content in noninfarcted regions and prevents the increase in right ventricular weight/body weight, and its effect is similar to captopril in rat model with myocardial infarction (MI). Metoprolol treatment tends to increase right ventricular weight and heart weight. [4]

Solubility Information

Solubility	DMSO: 250 mg/mL (365.06 mM), Sonication is recommended. H ₂ O: 34.2 mg/mL (49.94 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.4603 mL	7.3013 mL	14.6026 mL
5 mM	0.2921 mL	1.4603 mL	2.9205 mL
10 mM	0.146 mL	0.7301 mL	1.4603 mL
50 mM	0.0292 mL	0.146 mL	0.2921 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Sabbah HN, et al. J Am Coll Cardiol,2000, 36(5), 1698-1705.

Guo J, Xu Y, Chen LJ, et al. Gut Microbiota and Host Cyp450s Co-contribute to Pharmacokinetic Variability in Mice With Non-Alcoholic Steatohepatitis: Vary From Drug to Drug. Journal of Advanced Research. 2021

Babick A, et al. J Cell Physiol,2013, 228(10), 2063-2070.

Cui L, Xu F, Jiang Z, et al. Melatonin regulates proliferation and apoptosis of endometrial stromal cells via MT1. Acta Biochimica et Biophysica Sinica. 2021

Sharma V, et al. Am J Physiol Heart Circ Physiol,2008, 294(4), H1609-1620.

Wei S, et al. J Am Coll Cardiol,2000, 36(1), 276-281.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481